2 Firms Drive $13.1B Heart Disease Treatment Developer Deal
Bristol Myers Squibb has agreed to pay $13.1 billion for MyoKardia, a clinical stage biopharmaceutical company focused on developing treatments for heart disease, the companies said Monday, in a deal built...To view the full article, register now.
Already a subscriber? Click here to view full article